Abstract
Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Current HIV Research
Title: Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Volume: 7 Issue: 4
Author(s): Carelia Garcia-Moruja, Patricia Rueda, Carmen Torres, Jose Alcami, Francisco Luque and Antonio Caruz
Affiliation:
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Abstract: Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Export Options
About this article
Cite this article as:
Garcia-Moruja Carelia, Rueda Patricia, Torres Carmen, Alcami Jose, Luque Francisco and Caruz Antonio, Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680543
DOI https://dx.doi.org/10.2174/157016209788680543 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System
Mini-Reviews in Medicinal Chemistry A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Paracoccidioides spp. and Histoplasma capsulatum: Current and New Perspectives for Diagnosis and Treatment
Current Topics in Medicinal Chemistry Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism The Impact of Self-Assembly in Medicine and Pharmacology
Current Pharmaceutical Analysis A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets